Baseline characteristics and medical history
| Characteristic | All patients (n=299) | Subgroup aged <70 years (n=219) | Subgroup aged ≥70 years (n=80) |
| Eastern Cooperative Oncology Group performance status, n (%) | |||
| 0 | 81 (27) | 65 (30) | 16 (20) |
| 1 | 99 (33) | 70 (32) | 29 (36) |
| 2 | 20 (7) | 13 (6) | 7 (9) |
| Unknown | 99 (33) | 71 (32) | 28 (35) |
| Median (range) body mass index, kg/m2 | (n=206) 25 (17–50) | (n=147) 24 (17–50) | (n=59) 25 (17–40) |
| Ongoing hypertension, n (%) | 79 (26) | 49 (22) | 33 (41) |
| Prior antihypertensive therapy, n (%) | 51 (17) | 28 (13) | 23 (29) |
| Prior β-blocker therapy, n (%) | 27 (9) | 14 (6) | 13 (16) |
| Ongoing concomitant medications, n (%) | |||
| Analgesic | 219 (73) | 170 (78) | 49 (61) |
| Antibiotic | 69 (23) | 48 (22) | 21 (26) |
| Antidepressant | 65 (22) | 51 (23) | 14 (18) |
| Antidiabetic | 23 (8) | 16 (7) | 7 (9) |
| Diuretic | 22 (7) | 16 (7) | 6 (8) |
| Histological subtype, n (%*) | (n=171) | (n=135) | (n=36) |
| Serous | 148 (87) | 116 (86) | 32 (89) |
| Clear cell | 8 (5) | 7 (5) | 1 (3) |
| Endometrioid | 6 (4) | 5 (4) | 1 (3) |
| Other/missing* | 9 (5) | 7 (5) | 2 (6) |
| Stage at start of bevacizumab, n (%) | (n=298)† | (n=218)† | (n=80) |
| IIIB | 15 (5) | 11 (5) | 4 (5) |
| IIIC | 152 (51) | 104 (48) | 48 (60) |
| IV | 131 (44) | 103 (47) | 28 (35) |
| ‘High risk’ per Medical Research Council ICON7 definition‡ | 268 (90) | 199 (91) | 69 (86) |
| Surgery, n (%) | |||
| Primary debulking | 62 (21) | 48 (22) | 14 (18) |
| Interval debulking§ | 109 (36) | 87 (40) | 22 (28) |
| None | 128 (43) | 84 (38) | 44 (55) |
| Residual disease after primary debulking surgery, n (%) | (n=60)¶ | (n=46)¶ | (n=14) |
| No visible residuum | 11 (18) | 9 (20) | 2 (14) |
| <1 cm | 9 (15) | 8 (17) | 1 (7) |
| ≥1 cm | 40 (67) | 29 (63) | 11 (79) |
*Not mandatory to record data; denominators of 171, 135, and 36, respectively (representing patients for whom surgical records were available, although not necessarily including histological information), are used to calculate percentages; ‘other’ includes adenocarcinoma, mixed epithelial, mucinous, and papillary, each recorded in one patient.
†Missing in one patient.
‡Stage III with ≥1 cm residuum, any stage IV, or no surgery.
§Including three patients with intended primary surgery who had interval debulking surgery.
¶Details of residual disease missing in two patients.
ICON7, International Collaboration on Ovarian Neoplasms 7.